The comprehensive analysis of the studies revealed that, compared with the control group, the use of GLP 1RA was significantly associated with a higher risk of depression onset
Safety and Tolerability Considerations Semaglutide is generally well-tolerated when doses are increased slowly, but gastrointestinal side effectsnausea, vomiting, constipationare common during titration
Rotating Injection Sites to Reduce Skin Reactions Rotating injection sites moving at least 12 cm from the previous spot and alternating between body regions prevents lipohypertrophy and ensures consistent drug absorption
Pep keeps routine tracking simple, Phaze stands out for score-based motivation and data export, and MyFitnessPal and Cronometer remain the strongest generalist food databases with GLP-1 features added
Clinical trial data provides objective evidence about efficacy (24.2% weight loss at 48 weeks), safety (88.8% completion rate), side effects (peak at weeks 6-8, resolve by week 12 for most), and discontinuation outcomes (70-80% regain over 12-18 months, not immediately)
